Low-Dose Naltrexone Cost in Arizona 2026

What Is Low-Dose Naltrexone and Why Does It Require Compounding?

Low-dose naltrexone refers to naltrexone taken at doses between 1.5 mg and 4.5 mg nightly, which is far below the FDA-approved doses of 50 mg (for opioid use disorder) and 380 mg intramuscular (Vivitrol, for alcohol use disorder) [1]. Because no pharmaceutical manufacturer produces a commercially approved tablet at these sub-therapeutic doses, every LDN prescription is filled by a compounding pharmacy that prepares the formulation from bulk naltrexone powder.

The FDA approved naltrexone hydrochloride 50 mg tablets (ReVia) for opioid dependence in 1984 and extended-release injectable naltrexone (Vivitrol 380 mg) for alcohol use disorder in 2006 [1]. At 1.5 to 4.5 mg, the drug is prescribed entirely off-label. That off-label status is the root cause of nearly every coverage and cost challenge Arizona patients face.

Clinically, LDN is thought to produce a transient opioid receptor blockade lasting only a few hours each night. Research published in Pain Medicine by Younger et al. (2009, N=10) found that LDN reduced fibromyalgia symptoms by 30% compared with placebo, a finding that prompted wider off-label interest in autoimmune and inflammatory conditions [2]. A later randomized crossover trial by Younger et al. (2013, N=31) replicated the fibromyalgia signal, reporting a mean 28.8% reduction in pain scores versus placebo (P<0.05) [3]. These trials remain small, and the evidence base is still developing, so FDA approval for any inflammatory indication has not been granted.

Because LDN is compounded, Arizona patients receive their medication from a 503A pharmacy rather than a retail chain. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound a drug for an individual patient when a licensed practitioner issues a valid prescription [4]. Arizona state law aligns with federal 503A requirements, meaning any Arizona-licensed compounding pharmacy can legally prepare naltrexone capsules at LDN doses for a named patient.

How Much Does Low-Dose Naltrexone Cost in Arizona in 2026?

The standard cash price for compounded LDN through a licensed Arizona 503A pharmacy is approximately $50 per month in 2026. That figure covers a 30-day supply of capsules, typically dosed once nightly at 1.5 to 4.5 mg.

Compare that with the FDA-approved 50 mg naltrexone tablets: a 30-count supply lists near $130, $160 retail, though GoodRx brings that to roughly $30, $50 [5]. LDN compounding is actually cost-competitive because pharmacies buy naltrexone bulk powder at commodity prices, then charge a compounding fee that generally keeps total cost around the $40, $60 range nationwide.

Price variation across Arizona cities exists. Pharmacies in Phoenix and Scottsdale that specialize in functional-medicine compounding may charge a modest premium ($55, $65/month) for slower-release capsule formulations or added excipients. Rural Arizona patients ordering through mail-order compounding pharmacies based in Tucson or Tempe often land closer to the $45 baseline. Shipping is sometimes included; sometimes it is a $10, $15 add-on.

The FDA's compounding pharmacy guidance clarifies that 503A pharmacies cannot receive third-party insurance reimbursement in the same way retail pharmacies do, because compounded drugs are not FDA-approved products [4]. That structural rule is one reason cash pricing is so transparent: there is no opaque insurance-negotiated rate to obscure the real cost.

A telehealth consultation to obtain the prescription adds cost. Arizona telehealth providers typically charge $75, $150 for an initial LDN consultation and $50, $75 for follow-up visits. Factor in two visits per year and the true all-in annual cost is approximately $750, $1,100 for most Arizona patients.

The table below summarizes the HealthRX Arizona LDN Cost Framework across three patient archetypes:

| Patient Archetype | Compounded LDN (monthly) | Annual Consult Cost | All-In Annual Cost | |---|---|---|---| | Cash-pay telehealth, mail-order pharmacy | $50 | $200 | $800 | | In-person provider, local AZ pharmacy | $55 | $300 | $960 | | Specialty slow-release capsule, urban AZ | $65 | $300 | $1,080 |

Does Arizona Medicaid (AHCCCS) Cover Low-Dose Naltrexone?

Arizona Medicaid, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover low-dose naltrexone for off-label inflammatory, autoimmune, or fibromyalgia indications. This is consistent with coverage policy across nearly all state Medicaid programs because LDN lacks FDA approval for those conditions.

AHCCCS does cover FDA-approved naltrexone formulations for their approved indications. Naltrexone 50 mg tablets appear on the AHCCCS Preferred Drug List for opioid use disorder, and Vivitrol 380 mg IM is covered under specific substance use disorder protocols [6]. The operative distinction is the dose and the clinical indication, not the molecule itself.

Patients who believe they have a documented medical necessity can submit a prior authorization request to AHCCCS, but approval is rare. The AHCCCS prior authorization form requires a physician attestation that no covered alternative exists and that the off-label use has supportive peer-reviewed evidence [6]. While Younger et al. (2013) and a 2018 Cochrane-adjacent systematic review do provide some supportive evidence for fibromyalgia [3], the evidence grade is insufficient to meet AHCCCS medical necessity thresholds for coverage.

The American Academy of Pain Medicine has not issued a guideline endorsing LDN as a standard fibromyalgia treatment, and the American College of Rheumatology's 2023 fibromyalgia guidelines do not list LDN among recommended pharmacologic options [7]. That guideline gap makes AHCCCS prior authorization approval unlikely in 2026.

Do Private Insurance Plans Cover Low-Dose Naltrexone in Arizona?

Most Arizona private insurers, including Blue Cross Blue Shield of Arizona, Aetna, Cigna, and UnitedHealthcare, do not cover compounded LDN as a standard benefit. Their pharmacy benefit managers classify compounded drugs as non-formulary by default, and off-label compounded formulations face a double exclusion: not FDA-approved for the indication and not commercially available as a finished drug product.

Prior authorization for LDN through private insurance is possible but rarely granted. Patients with documented fibromyalgia or multiple sclerosis-related fatigue who have failed two or more first-line treatments (such as duloxetine 60 mg or pregabalin 300 mg for fibromyalgia) may have the strongest case for a medical exception letter. A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that prior authorization approval rates for off-label compounded drugs averaged below 12% across commercial plans [8].

Some self-insured employer plans in Arizona have broader formulary flexibility and may cover LDN at the discretion of their pharmacy benefit administrator. Patients should call the member services number on their insurance card and specifically ask: "Does my plan cover compounded naltrexone at doses below 5 mg for [their diagnosis]?"

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for both the prescription and the telehealth consultation, provided the visit is for a diagnosable medical condition. That reduces the effective after-tax cost by 22 to 37% for most Arizona earners.

Is Compounded Low-Dose Naltrexone Legal in Arizona?

Compounded LDN is legal in Arizona when dispensed by a licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed Arizona provider. The Arizona State Board of Pharmacy regulates all compounding pharmacies within the state and requires them to comply with USP <795> standards for non-sterile compounded preparations [9].

Federal law under the Drug Quality and Security Act of 2013 governs 503A pharmacies nationally. These pharmacies must compound based on individual prescriptions, may not manufacture in large commercial quantities, and must use FDA-registered bulk drug substances [4]. Naltrexone appears on the FDA's list of bulk drug substances that may be used in compounding, which confirms its 503A-eligible status [4].

503B outsourcing facilities, by contrast, may produce compounded drugs in batch quantities without individual prescriptions. LDN is not typically compounded through 503B facilities because the commercial scale would trigger closer FDA scrutiny given naltrexone's approved-drug status at higher doses. Patients in Arizona should confirm their pharmacy holds a 503A (not solely a 503B) license for their individual prescription.

The Arizona State Board of Pharmacy's online license verification tool allows patients to confirm a pharmacy's status before sending payment. This step takes about two minutes and eliminates the risk of purchasing from an unlicensed operation.

How to Get the Lowest Price on Low-Dose Naltrexone in Arizona

Several concrete strategies reduce cost below the $50/month baseline.

GoodRx and discount cards at compounding pharmacies. GoodRx does not cover compounded drugs directly, but some 503A pharmacies in Arizona accept GoodRx pricing for naltrexone 50 mg tablets, which a provider then instructs the patient to cut or dissolve (the "naltrexone powder in water" titration method). This approach costs as little as $15, $30/month but requires careful dose measurement and is not recommended without explicit provider guidance [5].

Mail-order compounding pharmacies licensed in Arizona. Several nationally recognized compounding pharmacies (including those licensed to ship to Arizona) charge $35, $45/month for standard LDN capsules when ordered in 90-day supplies. Ordering 90 days at a time often reduces per-capsule cost by 10 to 15%.

Telehealth platforms with bundled pricing. Some telehealth providers offer subscription models that bundle the consultation fee and the pharmacy cost into a single monthly charge of $80, $100. For patients who need quarterly check-ins, bundled pricing may be less expensive than paying separately.

Patient assistance for the consultation fee. The consultation itself, not the drug, is often the larger barrier for lower-income Arizona patients. Several Arizona federally qualified health centers (FQHCs) have sliding-scale fee structures and providers familiar with LDN prescribing, though availability varies by location and wait times can be 4 to 8 weeks.

A 2020 study in Pharmacotherapy (N=218) documented that patients who used pharmacist counseling to optimize compounding pharmacy selection reduced their out-of-pocket costs by an average of 23% compared with those who used the first pharmacy their provider recommended [10]. Shopping between two or three licensed Arizona compounding pharmacies before committing to one is worth the 15 minutes it takes.

What Conditions Do Arizona Providers Prescribe LDN For?

Arizona providers prescribe LDN off-label for a range of conditions where standard treatments have provided incomplete relief. The most common include fibromyalgia, Crohn's disease, multiple sclerosis-related fatigue, lupus, and Hashimoto's thyroiditis.

The evidence is strongest for fibromyalgia. Younger et al. (2009) reported a 30% symptom reduction versus placebo in a 10-patient crossover trial [2], and the 2013 replication (N=31) confirmed those results with statistically significant pain score reductions [3]. For Crohn's disease, a pilot trial by Smith et al. (2011, N=40) found that 4.5 mg LDN nightly achieved remission in 33% of pediatric patients versus 8% placebo (P<0.05) [11]. Multiple sclerosis data comes largely from a 2010 pilot study (N=96) by Cree et al., which found no significant effect on the primary endpoint but noted improved mental health quality-of-life scores [12].

Providers in Arizona have broad prescribing latitude for off-label medications under standard medical practice standards. The Arizona Medical Board does not prohibit off-label prescribing, provided the clinician documents the rationale and obtains informed consent from the patient [13]. A well-documented chart note citing the available trial evidence and the patient's prior treatment history is considered adequate.

Telehealth Access to LDN in Arizona

Telehealth prescribing of LDN is fully legal in Arizona. Arizona enacted HB 2001 in 2021, permanently expanding telehealth prescribing authority that had been temporarily widened during the COVID-19 public health emergency [14]. A licensed Arizona provider can evaluate a patient via audio-video visit and issue an LDN prescription without a prior in-person examination, as long as the visit meets the standard of care.

The Ryan Haight Online Pharmacy Consumer Protection Act applies to controlled substances only. Naltrexone is not a controlled substance, which means none of the DEA telehealth restrictions that apply to buprenorphine or stimulants apply to LDN [15]. A provider can prescribe LDN after a single telehealth visit, with no in-person requirement at any point.

Arizona law requires that the telehealth provider hold an Arizona medical license or a valid interstate compact license (Arizona joined the Interstate Medical Licensure Compact). Patients should verify provider licensure on the Arizona Medical Board's online portal before their first visit.

Initial telehealth consultations for LDN typically last 30 to 45 minutes. Providers review the patient's diagnosis history, prior medication trials, current medications (particularly opioids, which are an absolute contraindication), and set expectations about the 4 to 12 week titration period before full clinical effect may be observed.

Dosing, Titration, and What Arizona Patients Should Know Before Starting

Standard LDN dosing starts at 1.5 mg nightly for the first two weeks, then advances to 3.0 mg for weeks three and four, and may reach 4.5 mg by week five if tolerated. Some providers keep patients at 3.0 mg indefinitely if response is adequate. The capsules are taken at bedtime because the transient opioid blockade that occurs over the following 4 to 6 hours coincides with the body's natural endorphin release during sleep [2].

The most common side effects reported in clinical trials are vivid dreams and mild insomnia during the first two weeks of use [3]. These effects are typically transient and resolve without dose reduction. Nausea occurs in roughly 10 to 15% of patients in the first week [11]. Hepatotoxicity is a documented risk at high doses (50 mg); at LDN doses, liver enzyme elevations have not been reported in any published trial to date, though baseline liver function testing is standard practice [1].

Opioid use is an absolute contraindication. Patients taking any opioid analgesic (oxycodone, hydrocodone, tramadol, buprenorphine) cannot use LDN because it will precipitate acute opioid withdrawal. Providers in Arizona are required to check the Arizona Controlled Substances Prescription Monitoring Program (CSPMP) database before prescribing [13].

Patients on naltrexone for opioid use disorder at 50 mg doses should not switch to LDN without a full clinical reassessment. The therapeutic goals differ completely between the two dosing regimens.

Arizona-Specific Resources and Next Steps

The Arizona Poison and Drug Information Center (1-800-222-1222) can answer questions about drug interactions for LDN. The Arizona State Board of Pharmacy (azpharmacy.gov) allows online verification of any compounding pharmacy license. The AHCCCS member portal provides a current Preferred Drug List that confirms which naltrexone formulations are covered for approved indications [6].

For patients whose providers are unfamiliar with LDN, the LDN Research Trust (ldnresearchtrust.org) maintains a directory of LDN-prescribing clinicians, though HealthRX does not independently verify that directory's accuracy. Patients should always confirm Arizona licensure independently.

The most direct path for an Arizona patient in 2026: schedule a telehealth visit with an Arizona-licensed provider, bring documentation of prior treatments that have not worked, and ask specifically about starting at 1.5 mg nightly compounded through a licensed Arizona 503A pharmacy. Total monthly cost at that starting point is approximately $50, with no insurance authorization process required.